ImCheck to Present Updated Patient Response Data from the EVICTION Trial and Additional ICT01 Results at the SITC Annual Meeting 2021
Marseille, France, October 1, 2021 – ImCheck Therapeutics today announced that it will present updated clinical data from the ongoing EVICTION Phase I/IIa trial evaluating ICT01, a first-in-class Butyrophilin (BTN) 3A-targeting monoclonal antibody, alone and in combination with pembrolizumab in patients with advanced, relapsed/refractory solid and hematological cancers, in one oral presentation and one poster, as well as an additional poster covering preclinical evaluation of ICT01 in combination with a novel IL-2/IL-15 agonist, at the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting being held both in person and virtually from November 10 – 14, 2021.
“It is exciting to have the opportunity to present additional clinical data on ICT01 monotherapy and in combination with pembrolizumab from Part 1 of the ongoing EVICTION trial at SITC 2021. ImCheck continues to gather important patient and mechanistic data on ICT01 that will help us identify the right dose of ICT01 in the right patients, which will be the focus of Part 2 of the study,” said Paul Frohna, MD, PhD, Chief Medical Officer at ImCheck Therapeutics.
Details of the oral presentation are:
Presentation Title: “Clinical Activity of ICT01, an anti-BTN3A-Targeted, γ9δ2-Activating mAb, Alone and in Combination with Pembrolizumab in Patients with Advanced/Refractory Solid Tumors: EVICTION Trial”
Session Title: Concurrent Rapid Oral Abstract Presentation Session: Clinical
Abstract Number: 503
Speaker: Prof. Martin Wermke
Session Date/Time: November 12, 2021, 12:55 pm – 1:55 pm EST / 18:55 – 19:55 CET
Details of the poster presentations are:
Poster Title: “Correlation of baseline circulating Vg9Vd2 T cell counts and pharmacodynamic activity of ICT01 in cancer patients: preliminary results from EVICTION and a novel patient enrichment strategy”
Abstract number: 528
Session Date/Time: 11/12/2021, 7:00 am – 8:30 pm EST and as ePoster
Poster Title: “ICT01, an anti-BTN3A monoclonal antibody, and NL-201, an alpha-independent IL-2/IL-15 agonist, combine to elicit a potent anti-tumor response by synergistically stimulating Vg9Vd2 T cell activation and proliferation”
Abstract number: 563
Session Date/Time: 11/12/2021 7:00 am – 8:30 pm EST and as ePoster
About the EVICTION Trial
EVICTION is a first-in-human, dose escalation (Part 1) and cohort expansion (Part 2) clinical trial of ICT01 in patients with various advanced relapsed or refractory solid or hematologic cancers that have exhausted standard of care treatment options. Part 1 is a basket trial designed to characterize the preliminary safety, tolerability, and pharmacodynamic activity of ICT01 as monotherapy (Group A: solid tumors; Group B: hematologic tumors) and in combination with pembrolizumab (Group C: solid tumors). Group A includes bladder, breast, colorectal, gastric, melanoma, ovarian, prostate, and pancreatic cancer patients, Group B includes acute myeloid leukemia, acute lymphocytic leukemia, follicular lymphoma, and diffuse large B cell lymphoma patients, and Group C includes bladder, head and neck squamous cell carcinoma, melanoma, and non-small cell lung cancer patients. Basket trials are a clinical trial design that allows new drugs to be tested rapidly in a range of indications, providing initial data on multiple parameters that can contribute to an accelerated development timeline. More information on the EVICTION trial can be found at clinicaltrials.gov (NCT04243499).
ICT01 is a humanized, anti-BTN3A (also known as CD277) monoclonal antibody that selectively activates γ9δ2 T cells, which are part of the innate immune system that is responsible for immunosurveillance of malignancy and infections. The 3 isoforms of BTN3A targeted by ICT01 are overexpressed on a number of solid tumors (e.g., bladder, colorectal, melanoma, ovarian, pancreatic, lung) and hematologic cancers (e.g., leukemia & lymphoma) and also expressed on the surface of innate (e.g., γδ T cells and NK cells) and adaptive immune cells (T cells and B cells). BTN3A is essential for the activation of the anti-tumor immune response of γ9δ2 T cells.
As demonstrated in EVICTION data presented at AACR, ICT01 selectively activates circulating γ9δ2 T cells that leads to migration of γ9δ2 T cells out of the circulation and into target tissue (e.g., tumors), while also activating the tumor-resident γ9δ2 T cells to directly kill malignant cells, which is accompanied by secretion of two key inflammatory cytokines, IFNg and TNFa, that contribute to the expansion of the anti-tumor immune response. ICT01 has been shown to have anti-tumor activity against a range of cancers in in vitro and in vivo tumor models.
About IMCHECK THERAPEUTICS
ImCheck Therapeutics is designing and developing a new generation of immunotherapeutic antibodies targeting butyrophilins, a novel super-family of immunomodulators.
As demonstrated by lead clinical-stage program ICT01, which has a mechanism of action to simultaneously modulate innate and adaptive immunity, ImCheck’s “first-in-class” activating antibodies may be able to produce superior clinical results as compared to the first-generation of immune checkpoint inhibitors and, when used in combination, to overcome resistance to this group of agents. In addition, preclinical experiments with ImCheck’s antagonist antibodies have shown their potential as treatments for a wide range of autoimmune diseases.
Co-founder of the Marseille Immunopole cluster, ImCheck benefits from support from Prof. Daniel Olive (INSERM, CNRS, Institut Paoli Calmettes, Aix-Marseille Université), a worldwide leader in γδ T cells and butyrophilins research; from the experience of an expert management team; and from the commitment of leading US and European investors.
US and EU
+49 (0) 172 861 8540
The content is by GlobeNewswire. DKODING Media is not responsible for the content provided or any links related to this content. DKODING Media is not responsible for the correctness, topicality or the quality of the content.